In 2006, the first reported association between an antecedent exposure to gadolinium-based contrast media (GBCM) and the development of nephrogenic systemic fibrosis (NSF) ignited a debate on the safety of these agents in patients with kidney disease, with ensuing severe and appropriate-use restrictions put in place. In this issue of Kidney360, this debate is revived 15 years later, but with the tide reversing as their use is being reconsidered in these same patients. This debilitating, and often fatal, disease has fortunately receded into the background despite its antecedent exposure. Its practical disappearance can be credited to both the implementation of protocols limiting GBCM use in patients with impaired kidney function or those on maintenance dialysis and the contraindication in those with CKD stages 4–5 and those with ESKD. Nonetheless, its associated risk was quite high in two recent studies that included 154 patients with CKD stages 4–5 (3,4). These findings are seconded in the recent subanalysis of a large meta-analysis dataset with no patients with NSF identified among 2687 patients with CKD stages 4–5 who were exposed to group II GBCM (5,6).

Because I have already declared a position in favor of lifting restrictions on the use of group II GBCM in those with CKD (7), it is important to start this discussion by first heeding the expressed concerns raised by Pun and Crowley (8) in their con paper. The authors raise a number of important points, relying on data from a project of the US Veteran Affairs Evidence Synthesis Program (9). In 19 cohort studies and one nonrandomized trial with exclusive use of group II GBCM (except for one group III GBCM), no cases of NSF were identified in 83,291 patients. As noted, the CKD stages 3–5 subgroup represented <5% of the total, raising concern for representation and inclusiveness, especially that restrictive policies have likely excluded patients with CKD from getting GBCM. Nonetheless, there were no patients who developed NSF, including in patients with ESKD who were historically considered the most at risk with group I GBCM. In the recent, aforementioned subanalysis, there were 2666 patients with CKD stages 4–5 who were receiving either gadobenate or gadoterate, among whom 27% had CKD stage 5 and 32% received gadoterate. No patients with NSF were reported, with a recalculated risk of one in 694 exposed for this subgroup. Despite a smaller than desired number of collated patients with CKD stages 4–5 in cohort studies, the absence of NSF is reassuring. On the basis of NSF cases occurring in 40 patients with CKD stages 4–5, a modeled risk was calculated at one in 908 exposed to high-risk GBCM, and there was a predicted nil risk for low-risk GBCM.
| Classification per NSF risk | Chemical Name                  | Chelate Structure | Notes                                                                 |
|-----------------------------|-------------------------------|------------------|----------------------------------------------------------------------|
| ACR                         | EMA                          | ESUR             |                                                                      |
| Group I                     | High                          | Highest          | Gadodiamide                                                         | Linear nonionic | Contraindicated in those with CKD stages 4–5D and AKI Intravenous use suspended by EMA No longer marketed in the United States |
|                             | High                          | Highest          | Gadopentetate dimeglumine                                           | Linear ionic    | Contraindicated in those with CKD stages 4–5D and AKI Intravenous use suspended by EMA No longer marketed in the United States |
|                             | High                          | Highest          | Gadoversetamide                                                   | Linear nonionic | Contraindicated in those with CKD stages 4–5D and AKI Intravenous use suspended by EMA Withdrawn by marketing authorization holder in Europe in 2017 No longer marketed in the United States |
| Group II                    | Low                           | Lowest           | Gadoterate meglumine                                               | Macro cyclic ionic |                                                                      |
|                             | Low                           | Lowest           | Gadoteridol                                                       | Macro cyclic nonionic |                                                                      |
| Group II                    | Low                           | Lowest           | Gadobutrol                                                        | Macro cyclic nonionic |                                                                      |
| Group II                    | Medium                        | Intermediate     | Gadobenate dimeglumine                                             | Linear ionic    | Limited to hepatobiliary imaging by EMA                              |
| Group III                   | Medium                        | Intermediate     | Gadoxetate disodium                                               | Linear ionic    | Limited to hepatobiliary imaging by EMA                              |

Reprinted from ref. 7, with permission. Based on information provided in the ACR manual (1). NSF, nephrogenic systemic fibrosis; ACR, American College of Radiology; EMA, European Medicines Agency; ESUR, European Society of Urogenital Radiology.
This can be seen as reassuring because risk was infinitesimally small in CKD stages 4–5, even with high-risk agents, and practically nil with low-risk II GBCM.

Inherent limitations to all of the included studies are raised by the authors, such as the lack of standardized assessment for NSF, despite published diagnostic criteria (10), and repeated administrations. Of note, an interesting point is made about patients with risk factors for CKD not being included, although NSF risk has been confined to presence of CKD per se.

Informed consent is not recommended prior to GBCA group II injection, but deference is made to local practice preferences.

Rodby (11), on the pro side of this debate, presented an argument for unrestraining the use of group II GBCM in patients with CKD stages 4–5, supported by accumulating evidence for absence of NSF in the >3000 patients exposed to GBCM reported in recent papers. He made reference to the aforementioned recent stratified analysis by CKD stage at the request of the National Kidney Foundation in the United States (6). He cautioned against using more than the standard dose, a case in point made in a recently reported patient with CKD stage 3a who developed NSF after 185 days postexposure to 1.5 times the standard dose of the group II GBCM gadoterate (12). This was a major risk factor with group I GBCM and should be avoided with all GBCM. Important notes are made about the sole GBCM in group III being insufficiently studied in patients with CKD, and that direct GBCM nephrotoxicity is not a concern with standard intravenous dosing.

As the debate starts to move beyond the safety of low risk for NSF in group II GBCM in those with CKD stages 4–5, lingering concerns include the potential increase in patients developing NSF as the use of group II GBCM become more unrestricted (13) and the recently reported deposition of gadolinium in the brain, although to a lesser degree with group II GBCM in all patients (14). Other points worth mentioning are not initiating hemodialysis in patients with CKD stages 4–5 for the sole purpose of GBCM removal and, in contrast to patients with ESKD who are anuric, the risk of contrast-induced nephropathy with iodinated radiocontrast agents is germane to the discussion when assessing risk/benefit ratio in CKD stages 4–5, with the balance tipping in favor of using group II GBCM when needed. In this regard, it remains important to discuss with the radiologist all possible imaging options, including noncontrast magnetic resonance imaging, so as to limit the exposure to GBCM to that which is absolutely needed. This is especially true given that repeat administrations within a short period, or lifetime cumulative exposure, remain of concern.

In summary, the use of group II or low-risk GBCM will be expected to increase in the coming years in patients with CKD stages 4–5, allowing for better diagnostic information to be obtained, when necessary, in these patients. Although the preponderance of data from recent cohort studies support this approach, as with any matter still under debate, it is important to remain vigilant as clinicians, maintaining strict adherence to the set boundaries for safe use and promptly reporting any adverse events.

Acknowledgments
The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or Kidney360. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contribution
A. Abu-Alfa wrote the original draft and reviewed and edited the manuscript.

References
1. American College of Radiology Committee on Drugs and Contrast Media: Nephrogenic systemic fibrosis (NSF). In: ACR Manual on Contrast Media, Reston, VA, American College of Radiology, 2020, pp 83–91. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed October 4, 2020
2. Abu-Alfa AK: Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 18: 188–198, 2011 https://doi.org/10.1053/j.ackd.2011.03.001
3. Kanal E, Patton TJ, Krefting I, Wang C: Nephrogenic systemic fibrosis risk assessment and skin biopsy quantification in patients with renal disease following gadobenate contrast administration. AJNR Am J Neuroradiol 41: 393–399, 2020 https://doi.org/10.3174/ajnr.A6448
4. McWilliams RG, Frabizzio JV, De Backer AJ, Grinberg A, Maes BD, Zobel BB, Gottschalk A: Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadodate meglumine administration: The NSSafe study. J Magn Reson Imaging 51: 607–614, 2020 https://doi.org/10.1002/jmri.26851
5. Wollen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer I, Davenport MS: Risk of nephrogenic systemic fibrosis with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: A systematic review and meta-analysis. JAMA Intern Med 180: 223–230, 2020 https://doi.org/10.1001/jamainternmed.2019.5284
6. Shankar PR, Davenport MS: Risk of nephrogenic systemic fibrosis in stage 4 and 5 chronic kidney disease following group II gadolinium-based contrast agent administration: Subanalysis by chronic kidney disease stage. Radiology 297: 447–448, 2020
7. Abu-Alfa AK: Use of gadolinium-based contrast agents in kidney disease patients: Time for change. Am J Kidney Dis 76: 436–439, 2020 https://doi.org/10.1053/j.ajkd.2020.03.011
8. Pun PH, Crowley S: Group II GBCM can be used safely for imaging in stage 4/5 CKD patients: CON [published online ahead of print December 3, 2020]. Kidney360 2: 13–15, 2021 https://doi.org/10.34067/KID.00055720
9. Lunyera J, Mohottige D, Alexopoulos A-S, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM: Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: A systematic review. Ann Intern Med 173: 110–119, 2020 https://doi.org/10.7326/M20-0299
10. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE: Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol 85: 1095–1106.e7, 2021 https://doi.org/10.1016/j.jaad.2020.08.041
11. Rodby R: Group II GBCM can be used safely for imaging in stage 4/5 CKD patients: PRO [published online ahead of print December 3, 2020]. Kidney360 2: 10–12, 2021 https://doi.org/10.34067/KID.00057920
12. Lim YJ, Bang J, Ko Y, Seo HM, Jung WY, Yi JH, Han SW, Yu MY: Late onset nephrogenic systemic fibrosis in a patient with stage 3 chronic kidney disease: A case report. J Korean Med Sci 35: e293, 2020
13. Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HJ: Risks and options with gadolinium-based contrast agents in
patients with CKD: A review [published online ahead of print August 27, 2020]. *Am J Kidney Dis*

14. McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY: Gadolinium retention: A research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. *Radiology* 289: 517–534, 2018 https://doi.org/10.1148/radiol.2018181151

**Received:** October 7, 2020  **Accepted:** October 26, 2020

See related debates, “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO,” and “Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON,” on pages 10–12 and 13–15, respectively.